ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
31 hedge funds and large institutions have $21.7M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 6 closing their positions.
6% less funds holding
Funds holding: 33 → 31 (-2)
26% less capital invested
Capital invested by funds: $29.3M → $21.7M (-$7.67M)
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
93% less call options, than puts
Call options by funds: $1K | Put options by funds: $15K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.14M |
| 2 |
Morgan Stanley
New York
|
+$229K |
| 3 |
Renaissance Technologies
New York
|
+$65.6K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$61.9K |
| 5 |
WW
Waterfront Wealth
Overland Park,
Kansas
|
+$54.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$928K |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$689K |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$532K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$454K |
| 5 |
DMKJ
David M. Knott Jr
|
-$258K |
ASLN Hedge Fund Activity: Q1 2022 in Review
31 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q1 2022, worth a combined $21.7M — down 26% from $29.3M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ASLN and 4 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 7 added.
The largest buyer was Tang Capital Management, adding an estimated $1.14M. The largest seller was Silverarc Capital Management, cutting an estimated $928K.
- 31 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q1 2022, down from 33 in Q4 2021.
- Funds reported $21.7M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q1 2022, down 26% quarter-over-quarter.
- 4 funds opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q1 2022 and 6 closed out, a net change of -2 holders.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q1 2022 was Tang Capital Management, an estimated $1.14M added.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q1 2022 was Silverarc Capital Management, an estimated $928K sold.
Based on aggregated 13F filings for Q1 2022.